Document Detail

Structural and functional changes of carotid wall properties in patients with acromegaly are not restored after 1 year of GH/IGF1 normalization.
MedLine Citation:
PMID:  22426806     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To establish whether the ACM vascular changes in patients with effectively managed disease are different from those in patients with an active condition.
METHODS: 64 ACM patients were tested for serum GH (random and during an oral glucose tolerance test) and IGF1. Ultrasonography of the right common carotid (RCC) explored structural (the carotid diameter and intima-media thickness index (IMT)) and functional (the augmentation index (AIx), elastic modulus (Ep), and local pulse wave velocity (PWV)) arterial parameters in the ACM patients (groups A and B) and an age- and sex-matched control group of 21 patients without acromegaly (group C).
RESULTS: The ACM patients were divided into 2 subgroups that had similar cardiovascular risk factor profiles: A (n=10, with controlled ACM), and B (n=54, with active ACM). The AIx was higher in groups A (27.7% [2.2-54.3]) and B (20.0% [ - 38.2-97.1]) than in group C (3.5% [ - 11.3-31.1]), p=0.01 and 0.002, respectively. The group B patients presented with poorer functional carotid wall parameters than the control subjects: Ep-95.5 [33-280] KPa vs. 77.5 [39-146] KPa, p=0.01; and PWV-6 [3.6-10.4] m/s vs. 5.4 [3.9-7.2] m/s, p=0.03.The ACM patients had greater RCC diameters (6.4 ± 0.6 mm vs. 5.7 ± 0.6 mm, p<0.001) and IMT values (0.72 ± 0.13 mm vs. 0.58 ± 0.08 mm, p<0.001) than the subjects in group C.
CONCLUSIONS: Both the controlled and active ACM patients showed structural arterial changes. After 1 year of disease control, the patients with controlled ACM showed improvements in the functional, but not the structural, arterial parameters compared with the patients with an active condition.
S Găloiu; R Jurcuţ; A Vlădaia; A Florian; M Purice; B A Popescu; C Ginghină; M Coculescu
Related Documents :
7221766 - Leiomyoma of the ovary. a report of 3 cases.
12470406 - The effects of one- and two-stage orchiopexy on postoperative serum testosterone levels...
22714846 - Comparison of hearing recovery criteria in sudden sensorineural hearing loss.
25300706 - Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (w...
11371946 - Long-term outcome analysis of low pressure rectal reservoirs in 33 children with bladde...
23000936 - White-matter hyperintensities predict delirium after cardiac surgery.
Publication Detail:
Type:  Journal Article     Date:  2012-03-16
Journal Detail:
Title:  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association     Volume:  120     ISSN:  1439-3646     ISO Abbreviation:  Exp. Clin. Endocrinol. Diabetes     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-24     Completed Date:  2012-09-05     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9505926     Medline TA:  Exp Clin Endocrinol Diabetes     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  238-43     Citation Subset:  IM    
Copyright Information:
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / blood*,  pathology,  therapy,  ultrasonography
Blood Chemical Analysis / standards
Cardiovascular Diseases / blood,  etiology,  ultrasonography
Carotid Arteries / pathology,  physiopathology*,  ultrasonography*,  ultrastructure
Cross-Sectional Studies
Follow-Up Studies
Human Growth Hormone / blood*
Insulin-Like Growth Factor I / analysis*
Middle Aged
Recovery of Function
Reference Values
Time Factors
Reg. No./Substance:
12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Heritability of body mass index in pre-adolescence, young adulthood and late adulthood.
Next Document:  Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor...